基于以往涉及冠狀病毒疫苗的相關(guān)專利信息，對(duì)其現(xiàn)狀和發(fā)展趨勢(shì)進(jìn)行分析。自從2002年嚴(yán)重急性呼吸道系統(tǒng)綜合征（SARS）暴發(fā)以來(lái)，冠狀病毒疫苗專利申請(qǐng)量在2003年達(dá)到高峰；自從2012年中東呼吸綜合征暴發(fā)以來(lái)，冠狀病毒疫苗專利申請(qǐng)量在2012~2015年有小幅增長(zhǎng)。從重點(diǎn)申請(qǐng)人和疫苗類型的分析得出，目前針對(duì)冠狀病毒以核酸疫苗、滅活疫苗和病毒載體疫苗為主，這也與我國(guó)和美國(guó)已經(jīng)進(jìn)入臨床試驗(yàn)的新型冠狀病毒（SARS-CoV-2）3類疫苗類型相吻合。

Based on the patent information related to coronavirus vaccine, the present situation and development trend of coronavirus vaccine have been analyzed. Since the outbreak of SARS in 2002, the amount of patent applications of coronavirus vaccine reached the peak in 2003. Since the outbreak of Middle East respiratory syndrome in 2012, there was a small increase on the amount of patent applications of coronavirus vaccine from 2012 to 2015. In view of the analyses of the key applicants and vaccine types, it is concluded that nucleic acid vaccine, inactivated vaccine and viral vector vaccine are the main vaccine types against coronavirus, which is consistent with the three types of vaccines that have entered clinical trials in China and the United States.